Tcelltech GmbH
Tcelltech is a spin-out from the German Cancer Research Center (DKFZ) specializing in enabling technologies for next-generation cancer immunotherapies. The company has developed two main technology platforms: selecTCR, an AI bioinformatics platform for identifying tumor-reactive T cell receptors, and nanoSMAR, a high-performance gene expression DNA vector platform for cell and gene therapy. Tcelltech's mission is to overcome challenges in immunotherapy manufacturing, cost, and target identification to benefit more patients. They offer peptide vaccines, including IDH1 SCA-VAC and H3 SCA-VAC, and a T cell therapy product, TCT-001, which utilizes their nanoSMAR platform. The company is actively seeking licensing partners for its nanoSMAR technology.
Tcelltech GmbH
Tcelltech is a spin-out from the German Cancer Research Center (DKFZ) specializing in enabling technologies for next-generation cancer immunotherapies. The company has developed two main technology platforms: selecTCR, an AI bioinformatics platform for identifying tumor-reactive T cell receptors, and nanoSMAR, a high-performance gene expression DNA vector platform for cell and gene therapy. Tcelltech's mission is to overcome challenges in immunotherapy manufacturing, cost, and target identification to benefit more patients. They offer peptide vaccines, including IDH1 SCA-VAC and H3 SCA-VAC, and a T cell therapy product, TCT-001, which utilizes their nanoSMAR platform. The company is actively seeking licensing partners for its nanoSMAR technology.